Initial experience with a new transvenous defibrillation system.
The clinical efficacy and safety of a new bidirectional transvenous defibrillation endocardial lead system (ELS) was studied in 39 patients with ventricular tachycardia (VT) or fibrillation (VF). There were 28 patients with coronary disease and 11 patients with nonischemic VT/VF. Fourteen patients received the ELS combined with antitachycardia pacing devices (Ventak PRx 1700, CPI) and 25 patients with the Ventak P or P2 (CPI). Implantation of the ELS was attempted in 47 patients. Intraoperatively, the mean defibrillation threshold (DFT) was > 25 joules in five patients and no reliable ELS position was found in three other patients. These eight patients underwent thoracotomy and epicardial leads implantation. The mean DFT was < or = 20 joules in all 39 patients and the mean DFT was 18 joules. During the mean follow-up of 8 +/- 2 months two patients (5%) died suddenly. Complications occurred in two patients (5%).
Trappe
H J
HJ
Department of Cardiology, University Hospital Hannover, Germany.
Klein
H
H
Fieguth
H G
HG
Kielblock
B
B
Wenzlaff
P
P
Lichtlen
P R
PR
D006328:Cardiac Catheterization; D002304:Cardiac Pacing, Artificial; D017147:Defibrillators, Implantable; D004567:Electrodes, Implanted; D004699:Endocardium; D004867:Equipment Design; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D010138:Pacemaker, Artificial; D017180:Tachycardia, Ventricular / Q000175:diagnosis / Q000453:epidemiology / Q000628:therapy*; D013997:Time Factors; D014693:Ventricular Fibrillation / Q000175:diagnosis / Q000453:epidemiology / Q000628:therapy*